The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence

Ignatiadis, Michail; Azim, Hatem A.; Desmedt, Christine; Veys, Isabelle; Larsimont, Denis; Salgado, Roberto; Lyng, Maria Bibi; Viale, Giuseppe; Leyland‐Jones, Brian; Giobbie‐Hurder, Anita; Kammler, Rosita; Dell’Orto, Patrizia; Rothé, Françoise; Laı̈os, Ioanna; Ditzel, Henrik J.; Regan, Meredith M.; Piccart, Martine; Michiels, Stefan; Sotiriou, Christos

doi:10.1001/jamaoncol.2015.4377

Cited by 23 publications

(10 citation statements)

References 30 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ki67 has become an important pathological biomarker in routine clinical practice, and can improve the accuracy of pathological models to determine distant BC recurrence. 22 Although our quantitative data was incomplete, our Ki67 results statistically different between age groups, similar to previous studies, indicating that the recommended cut-off value of 14% was meaningful and suitable.…”

Section: Baseline Clinicopathological Features Of Breast Cancersupporting

confidence: 86%

Clinicopathological features and survival of early stage breast cancer in northwest China: A population‐based retrospective study of 1287 patients

Wang

Jiao

et al. 2017

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundBreast cancer (BC) displays different clinicopathological features and outcomes based on patient age, molecular subtype, and treatment. However, such features in BC patients in northwest China are unclear. This study investigated the clinicopathological features and overall survival (OS) of early stage BC patients using a population‐based study.MethodsPatients who were newly diagnosed with BC at the First Affiliated Hospital of Xi'an Jiaotong University between January 2001 and June 2012 were included. Clinicopathological features and OS were assessed.ResultsThe median age of 1287 patients was 50 years, with an average tumor size of 2.65 cm. Additionally, 42.7% were luminal A, 25.6% luminal B, 9.3% Her2 overexpression, and 17.7% triple negative. The cut‐off age was 35 years, and young patients (< 35) tended to have larger tumors, ≥ 4 positive lymph nodes, grade 2 or 3 histology, non‐luminal types, high Ki67, and poor outcomes. Patients with luminal A tumors showed moderate features: 50.6% had tumors < 2 cm, 56.7% had negative lymph nodes. Patients with Her2 overexpression tumors showed aggressive features and the poorest survival (5‐year OS 67.6%). Patients with triple negative tumors were the youngest (average 48.4 years), but had the largest proportion of grade 3 histology and poor outcomes.ConclusionOur results are consistent with those in other provinces in China, but showed an earlier age at diagnosis and more aggressive pathological features compared to developed countries. Additionally, each molecular subtype showed specific features and different survival outcomes.

show abstract

Section: Baseline Clinicopathological Features Of Breast Cancersupporting

confidence: 86%

Clinicopathological features and survival of early stage breast cancer in northwest China: A population‐based retrospective study of 1287 patients

Wang

Jiao

et al. 2017

Thoracic Cancer

View full text Add to dashboard Cite

show abstract

“…The GGI was investigated alongside other signatures in a large cohort of 2833 patients, highlighting the importance of proliferation-associated genes in breast cancer prognostication [29]. Subsequent evaluation in various clinical cohorts demonstrated the utility of this signature, relative to other measures of a tumours proliferative capacity (Ki67 staining, histological grade, mitotic activity) for predicting disease free survival [42][43][44][45][46][47].…”

Section: Commercially Available Mrna-based Diagnostic Testsmentioning

confidence: 99%

Molecular signatures in breast cancer

Lal

Reed

Luca

et al. 2017

Methods

View full text Add to dashboard Cite

The use of molecular signatures to add value to standard clinical and pathological parameters has impacted clinical practice in many cancer types, but perhaps most notably in the breast cancer field. This is, in part, due to the considerable complexity of the disease at the clinical, morphological and molecular levels. The adoption of molecular profiling of DNA, RNA and protein continues to reveal important differences in the intrinsic biology between molecular subtypes and has begun to impact the way patients are managed. Several bioinformatic tools have been developed using DNA or RNA-based signatures to stratify the disease into biologically and/or clinically meaningful subgroups. Here, we review the approaches that have been used to develop gene expression signatures into currently available diagnostic assays (e.g. OncotypeDX® and Mammaprint®), plus we describe the latest work on genome sequencing, the methodologies used in the discovery process of mutational signatures, and the potential of these signatures to impact the clinic.

show abstract

“…The P130 and P107 proteins have considerable sequence homology compared with Rb [45–47], and are regulated by G1 cyclin-dependent kinases [48]. Ki67 is a proliferation indicator [49] that determines the risk of distant tumor recurrence [50]. …”

Section: Discussionmentioning

confidence: 99%

Aurora kinase A revives dormant laryngeal squamous cell carcinoma cells via FAK/PI3K/Akt pathway activation

Yang

He²,

Chen³

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Revival of dormant tumor cells may be an important tumor metastasis mechanism. We hypothesized that aurora kinase A (AURKA), a cell cycle control kinase, promotes the transition of laryngeal squamous cell carcinoma (LSCC) cells from G0 phase to active division. We therefore investigated whether AURKA could revive dormant tumor cells to promote metastasis. Western blotting revealed that AURKA expression was persistently low in dormant laryngeal cancer Hep2 (D-Hep2) cells and high in non-dormant (T-Hep2) cells. Decreasing AURKA expression in T-Hep2 cells induced dormancy and reduced FAK/PI3K/Akt pathway activity. Increasing AURKA expression in D-Hep2 cells increased FAK/PI3K/Akt pathway activity and enhanced cellular proliferation, migration, invasion and metastasis. In addition, FAK/PI3K/Akt pathway inhibition caused dormancy-like behavior and reduced cellular mobility, migration and invasion. We conclude that AURKA may revive dormant tumor cells via FAK/PI3K/Akt pathway activation, thereby promoting migration and invasion in laryngeal cancer. AURKA/FAK/PI3K/Akt inhibitors may thus represent potential targets for clinical LSCC treatment.

show abstract

The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence

Abstract: clinicaltrials.gov Identifiers: NCT00004205 and NCT00004205.

Cited by 23 publications

References 30 publications

Clinicopathological features and survival of early stage breast cancer in northwest China: A population‐based retrospective study of 1287 patients

Clinicopathological features and survival of early stage breast cancer in northwest China: A population‐based retrospective study of 1287 patients

Molecular signatures in breast cancer

Aurora kinase A revives dormant laryngeal squamous cell carcinoma cells via FAK/PI3K/Akt pathway activation

Contact Info

Product

Resources

About